{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:16:55Z","timestamp":1791911815867,"version":"4.3.4"},"reference-count":68,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>We aimed to perform a structured literature review of spinal radiographic progression, as assessed by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), in patients with ankylosing spondylitis (AS) or nonradiographic axial spondyloarthritis (nr-axSpA) treated with biologic therapy. Searches were limited to English language manuscripts published in the 11\u2009years prior to 9 July 2019. Randomized controlled trials, open-label extensions (OLEs) and observational studies reporting mSASSS progression in patients with AS or nr-axSpA treated with biologics were eligible for inclusion. Bias was assessed using the methodological index for nonrandomized studies (MINORS) tool. Among the 322 studies identified in the literature search, 23 (11 OLEs and 12 cohort studies) met the eligibility criteria and were selected for inclusion. Most studies reported mSASSS progression in patients with AS receiving tumor necrosis factor inhibitor (TNFi) treatment. One study reported mSASSS progression in patients with AS treated with secukinumab, an interleukin-17A inhibitor. The mean (range) MINORS score was 11.3 (7\u201315) for the 15 noncomparative studies and 15 (12\u201322) for the 8 comparative studies. Although results of the individual studies were variable, mSASSS progression in patients with AS was generally minimal and slow with long-term TNFi therapy. Moreover, odds ratios for the likelihood of mSASSS progression with\/without TNFi favoured TNFi therapy in several of the cohort studies. The rate of mSASSS progression following continuous secukinumab treatment was low and remained stable over 4\u2009years. Of two studies reporting progression in patients with nr-axSpA treated with TNFis, one showed no mSASSS progression; however, the lack of control limited comparative conclusions.<\/jats:p>","DOI":"10.1177\/1759720x20906040","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T05:18:26Z","timestamp":1583299106000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":50,"title":["Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr-Universit\u00e4t Bochum, Claudius Stra\u00dfe 45, 44649, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Rheumatology Institute of Lucania (IReL) and Rheumatology Department of Lucania, San Carlo"},{"name":"Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio G.","family":"Favalli","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"de Peyrecave","sequence":"additional","affiliation":[{"name":"UCB Pharma, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone E.","family":"Auteri","sequence":"additional","affiliation":[{"name":"UCB Pharma, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan, and ASST Pini-CTO Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"bibr1-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2014.10.007"},{"key":"bibr2-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.04.002"},{"key":"bibr3-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1177\/2040622317743486"},{"key":"bibr4-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1493-8"},{"key":"bibr5-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"bibr6-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211544"},{"key":"bibr7-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"bibr8-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1002\/art.39298"},{"key":"bibr9-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X17706454"},{"key":"bibr10-1759720X20906040","unstructured":"Food and Drug Administration. Highlights of prescribing information: CIMZIA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125160s237lbl.pdf (2019, accessed 1 October 2019)."},{"key":"bibr11-1759720X20906040","unstructured":"Food and Drug Administration. Highlights of prescribing information: COSENTYX. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125504s001s002lbl.pdf (2016, accessed 1 August 2018)."},{"key":"bibr12-1759720X20906040","unstructured":"European Medicines Agency. Cosentyx (secukinumab) Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003729\/WC500183129.pdf (2015, accessed 1 August 2018)."},{"key":"bibr13-1759720X20906040","unstructured":"Eli Lilly and Company. Highlights of Prescribing Information Taltz\u00ae (ixekizumab). https:\/\/pi.lilly.com\/us\/taltz-uspi.pdf (2019, accessed 10 September 2019)."},{"key":"bibr14-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029728"},{"key":"bibr15-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124206"},{"key":"bibr16-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000396"},{"key":"bibr17-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.3310\/hta20090"},{"key":"bibr18-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005468.pub2"},{"key":"bibr19-1759720X20906040","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"Haroon N","year":"2013","journal-title":"Arthritis Rheum"},{"key":"bibr20-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-017-0681-5"},{"key":"bibr21-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1002\/art.23471"},{"key":"bibr22-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1002\/art.23901"},{"key":"bibr23-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1186\/ar2794"},{"key":"bibr24-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1002\/art.20446"},{"key":"bibr25-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205178"},{"key":"bibr26-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key128"},{"key":"bibr27-1759720X20906040","first-page":"2048","volume":"32","author":"Van der Heijde D","year":"2005","journal-title":"J Rheumatol"},{"key":"bibr28-1759720X20906040","unstructured":"York Health Economics Consortium. York Health Economics Consortium. https:\/\/www.yhec.co.uk\/glossary\/structured-review\/ (2016, accessed 25 January 2019)."},{"key":"bibr29-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3415-x"},{"key":"bibr30-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1177\/2048872617700873"},{"key":"bibr31-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"bibr32-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x"},{"key":"bibr33-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081033"},{"key":"bibr34-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202698"},{"key":"bibr35-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160594"},{"key":"bibr36-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"},{"key":"bibr37-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212377"},{"key":"bibr38-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key375"},{"key":"bibr39-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2018.1506822"},{"key":"bibr40-1759720X20906040","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1002\/art.30627","volume":"63","author":"Pedersen SJ","year":"2011","journal-title":"Arthritis Rheum"},{"key":"bibr41-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2015.09.006"},{"key":"bibr42-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168958"},{"key":"bibr43-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177231"},{"key":"bibr44-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23097"},{"key":"bibr45-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13270"},{"key":"bibr46-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1002\/art.40661"},{"key":"bibr47-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3684"},{"key":"bibr48-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1911-1"},{"key":"bibr49-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001170"},{"key":"bibr50-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.11.006"},{"key":"bibr51-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02668"},{"key":"bibr52-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.002"},{"key":"bibr53-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000187"},{"key":"bibr54-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.09.015"},{"key":"bibr55-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.02.007"},{"key":"bibr56-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14956.1"},{"key":"bibr57-1759720X20906040","first-page":"712","volume":"19","author":"Baraliakos X","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"bibr58-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez363"},{"key":"bibr59-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2009.11.015"},{"key":"bibr60-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201252"},{"key":"bibr61-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1186\/ar4144"},{"key":"bibr62-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10264"},{"key":"bibr63-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000186"},{"key":"bibr64-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206971"},{"key":"bibr65-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacr.2004.09.013"},{"key":"bibr66-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00106"},{"key":"bibr67-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.02.002"},{"key":"bibr68-1759720X20906040","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.01.014"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X20906040","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X20906040","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X20906040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:36:36Z","timestamp":1777588596000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X20906040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":68,"alternative-id":["10.1177\/1759720X20906040"],"URL":"https:\/\/doi.org\/10.1177\/1759720x20906040","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"1759720X20906040"}}